个人信息
Personal Information
联系方式
Contact Information
个人简介
Personal Profile
蒋莉,女,同济大学上海国际知识产权学院副教授,主要研究领域:专利法、科技法、生物技术伦理,具有专利代理人和法律职业资格,在springer出版英文专著Regulating Human Embryonic Stem Cell in China- A Comparative Study on Human Embryonic Stem Cell’s Patentability and Morality in US and EU,发表sci/ssci/cssci收录等核心期刊论文十余篇, 主持国家社科、司法部、中国法学会、江苏省社科、中国博士后特别资助等省部级课题十余项,参与德国联邦教育及研究部课题等国际合作课题。担任Journal of law and the Biosciences, Asia Pacific Law Review,Biosocieties, Stem Cell Translational Medicine,Pharmaceutical Patent Analyst等ssci/sci收录国际期刊审稿人。
1. 主持人,基因编辑技术的全球治理研究(19SFB2058), 国家司法与法治理论研究课
题,2019
2. 主持人,伦理困境下基因编辑法律问题研究(18CFX066),国家社会科学基金,2018
2. 主持人,基因编辑法律治理研究(2018T110535),中国博士后特别资助,2018
3. 主持人,人类基因编辑立法规制研究(CLS(2017)Y12),中国法学会,2017
4. 主持人,生物技术革命中专利伦理问题及其应对研究(17ZXC003),江苏省社会科学
基金,2017
5. 主持人,技术发展中专利伦理问题研究(17SFB3028),国家司法与法治理论研究课
题,2017
6. 主持人,知识产权法伦理规制研究(2016M590503),中国博士后基金会面上资助项
目,2016
7. 主持人,知识产权法伦理问题研究,江苏省教育厅高校哲学社会科学研究项目,2016
8. 主要参与人,GenE-Type: A Biomedical, Ethical and Legal analysis of Modern
Techniques of Genome Editing and its Potential Application, 德国联邦教育及研究
部, 2017
著作
Li Jiang, Regulating Human Embryonic Stem Cell in China- A Comparative Study on Human Embryonic Stem Cell’s Patentability and Morality in US and EU, (2016), Springer (施普林格出版社)
论文
1. 蒋莉,《基因编辑植物法律规制的困境与出路》,载《法学》2023年第5期。
2. Li Jiang and Hong Yang, “Generic Drugs and Innovative Drug Incentives: Early Dispute Resolution Mechanism in China” (2022) 41 Biotechnology Law Report 186-193. (SCI四区)
3. Li Jiang, “14-Day limit of human embryo research: moral issues in the patent law in China” (2021) 40 Biotechnology Law Report 393-408. (SCI四区)
4. Li Jiang, “Commercialization of the gene-edited crop and morality: challenges from liberal patent law and strict GMO law in the EU” (2020) 39 New Genetic and Society 191-218. (SSCI 三区)
5. Li Jiang,“Alienation from the Objectives of the Patent System: How to Remedy the Situation of Biotechnology Patent” (2019) 25 Science and Engineering Ethic 791-811. (SSCI二区)
6. Li Jiang and Achim Rosemann,“Human embryo gene editing in China: the uncertain legal status of the embryo”(2018)14 BioSocieties 46-66. (SSCI三区)
7. Li Jiang,“Centralised Intellectual Property Administrative Management Reform in China: Why it is needed and whether it works” (2018) 111 Intellectual Property Forum 19-24
8. 蒋莉,《基因编辑和人类生殖:社会伦理和法律规制》,《苏州大学学报法学版》,2018年第4期
9. 蒋莉,《人类基因编辑应有法可依》,载《中国社会科学报》2018年2月7日第1390期。
10. Achim Rosemann, Xin Qing Zhang and Li Jiang, “Human Germ Line Gene Editing: Why Comparative, Cross-National Studies of Public Viewpoints are Important” (2017) 5 Anthropology 175-178.
11. Li Jiang and Bing He Dong,“Fraudsters Operate and Officialdom Turns a Blind Eye: a Proposal for Controlling Stem Cell Therapy in China” (2016) 19 Medicine, Health Care and Philosophy 403-410. (SSCI 二区)
12. Li Jiang , “Will Wild East End Scientific Feast-the First Administrative Measure on Clinical Stem Cell Research in China” (2016) 35 Biotechnology Law Report 27-35. (SCI四区)
13. Li Jiang , “Will Diversity Regulations Disadvantage Human Embryonic Stem Cell Research: a Comparison between EU and US” (2014) 25 Depaul Journal of Art, Technology and Intellectual Property Law 53-90.
14. Li Jiang , “Between Scylla and Charybdis: Patentability And Morality Related To Human Embryonic Stem Cells”(2015)6 American University Intellectual Property Brief 53-97.
15. Li Jiang and Wei Shi, “Space for Flexibility: Lessons from the European Union Harmonization Model in Human Embryonic Stem Cell Regulation” (2014) 97 Intellectual Property Forum 63-68.

文件上传中...